Amarin's Inflection: Partnered International Growth Offsets U.S. Erosion
Q2 2026 shows Recordati-fueled European momentum, rising cash, and a leaner cost base — but U.S. pricing pressure and an operating loss keep the story in transition.
AMRN · Earnings Call · 2026-07-29
The International Inflection
Amarin's second-quarter 2026 earnings call was framed by CEO Aaron Berg as a turning point:
The successful implementation of these actions has resulted in a scalable business model while defining a clear path towards sustainable growth and profitability.
The catalyst is the exclusive licensing and supply agreement with Recordati, signed in June 2025, which has already exceeded expectations. In-market demand for VASCEPA/VAZKEPA across the global partner network rose 59% year-over-year, and in Europe specifically, demand surged 69% versus Q2 2025. The company now counts VAZKEPA as commercially available in 11 European countries, with a recent launch in Romania and particularly strong adoption in Spain, the U.K., and Italy.
What makes this international growth notable is not just the pace but the leverage it provides. Under Recordati's larger commercial infrastructure, Amarin is extracting more value than it could have achieved alone. Berg highlighted the contrast in prepared remarks: "The commercial momentum generated by Recordati thus far materially exceeds historical European growth rates achieved by Amarin prior to the licensing transaction." In the Q&A, he noted that Recordati is exploring territories Amarin would never have considered, while the path to larger markets like France remains a future milestone — "We'd like to see the ability to launch in France; that would be, of course, sometime in the future." “They're also evaluating a number of other countries. I mean ultimately, we'd like to see the ability to launch in France; that would be, of course, sometime in the future.” — Aaron Berg, Chief Executive Officer · 2026-07-29
This transformation is also reflected in the company's scientific positioning. The residual cardiovascular risk narrative remains central, supported by new post-hoc analyses of REDUCE-IT and updated guideline endorsements. The company is pairing commercial momentum with evidence generation, a strategy that undergirds its scientific exchange with partner organizations.
The Financial Transformation
Financially, the restructuring that began in mid-2025 is largely complete. Total operating expenses declined 59% year-over-year (38% excluding restructuring charges) to $27.0 million, driven by the $70 million annualized cost-savings plan. SG&A fell 43% to $22.2 million. The operating loss narrowed to $12.0 million from $16.0 million a year ago, and the company delivered positive cash flow from operations for the third consecutive quarter — $7.0 million in Q2. Inventory management also contributed: inventory dropped $19.5 million sequentially and $31.8 million from year-end.
The improved cash position is a key pillar. Effective net cash stood at $308 million, up from $303 million at year-end 2025, with no debt. CFO Peter Fishman reiterated confidence in full-year 2026 positive cash flow, building on prior commentary from the Q1 2026 call: “we are confident that as we've turned into a cash flow positive position that, that will continue into the future.” — Peter Fishman, Chief Financial Officer · 2026-04-29
However, margins remain pressured. The shift to a partnered model, combined with U.S. generic competition, pushed gross margin down to 39.4% in Q1 2026 (latest filed) — a far cry from the 79% peak. In Q2, cost of goods sold rose 22% due to regaining a PBM exclusive, which Fishman explained: “the increase is due to regaining that PBM exclusive.” — Peter Fishman, Chief Financial Officer · 2026-07-29 The U.S. business remains profitable on a contribution basis, but net pricing continues to erode as generics intensify.
The Path Ahead
Amarin has now provided a full-year 2026 outlook for certain key metrics, reflecting the greater visibility under the new model. The company continues to evaluate strategic alternatives with Barclays, and a share repurchase program remains authorized but not yet utilized. "We understand our responsibility to deploy capital in a way that benefits shareholders," Berg noted, but any action is likely to wait until the organic growth trajectory is more firmly established.
For investors, the inflection is real but not yet fully priced. The stock has drifted sideways over the past 90 days (down ~3%), and the full history still shows a >97% drawdown from its 2019 peak. The story hinges on whether the international ramp can outpace U.S. decline — and whether the company can translate early demand growth into sustainable revenue and profitability. The cash generation and evidence-based approach provide a foundation, but the next few quarters will be critical to validate the inflection.
The shift away from a direct U.S.-centric model toward a partnered global model is a fundamental transformation. As Berg said on the Q1 2026 call about Recordati's role, "they will have full controlled commercialization by the end of the year" — “they will have full controlled commercialization by the end of the year.” — Aaron D. Berg, Chief Executive Officer · 2025-07-30 That control is now showing up in the numbers, albeit from a low base. The coming quarters will reveal whether this market access expansion can drive the acceleration Amarin has promised.